![Joanne M. Conroy, M.D., headshot. Leadership Dialogue. A conversation with AHA Chair Joanne M. Conroy, M.D., and Robert Brady, Director of Anxiety Disorders Service, Dartmouth Health.](/sites/default/files/2024-07/leadership-dialogue-conroy-brady-900x400.jpg)
The Food and Drug Administration authorized a revised dosing regimen for the combination monoclonal antibody therapy Evusheld when used to prevent COVID-19 in certain patients, citing data showing a higher initial dose may better prevent infection by certain omicron subvariants.